Silence Therapeutics (SLNCF) 3.4800 $SLNCF
Amarantus elects Iain Ross to board
M2 - Mon Sep 01, 3:29AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) revealed on Friday the addition of Iain Ross to its board of directors.
Pulmonary Hypertension - Pipeline Review, H1 2014
M2 - Wed Jun 25, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/289bcz/pulmonary) has announced the addition of the "Pulmonary Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Activaero GmbH - Bayer AG - Ikaria Inc. - Proreo Pharma AG - Sanofi - Silence Therapeutics plc - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/289bcz/pulmonary
Global RNA Interference (RNAi) Therapy Market Outlook 2018
M2 - Tue Apr 01, 6:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hthtnb/global_rna) has announced the addition of the "Global RNA Interference (RNAi) Therapy Market Outlook 2018" report to their offering. The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry. Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts. There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be undruggable by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market. The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. With human proof of concept demonstrated, it is most likely that the RNAi companies would reformulate new delivery technology and enjoy the benefits. Global RNAi Therapy Report Findings: - Number of RNAi Based Drugs in Clinical Trials: 151 - Highest RNAi Clinical Trial in Preclinical Phase - Oncology Dominating the RNAi Based Drugs Clinical Trial Process - US Dominates RNAi Market & Clinical Trial Landscape Key Topics Covered: 1. Introduction to RNA Interference (RNAi) Therapy 2. Benefits of RNA Interference (RNAi) Therapy 3. RNA Interference (RNAi) Drug Delivery Mechanics 4. Global RNA Interference (RNAi) Therapy Market Overview 5. Global RNA Interference (RNAi) Market Dynamics 6. RNAi Clinical Pipeline by Phase, Indication & Country 7. Suspended & Discontinued RNAi Profiles 8. Competitive Landscape Companies Mentioned - Arrowhead Research - Alnylam Pharmaceuticals - Benitec Biopharma - Dicerna Pharmaceuticals - InteRNA Technologies - Isis Pharmaceuticals - RXi Pharmaceuticals - Santaris Pharma - Silence Therapeutics - Tekmira Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/hthtnb/global_rna
Global RNAi Drug Delivery Market 2014-2018: Read What's Trending
M2 - Wed Feb 19, 12:15PM CST
Research and Markets (http://www.researchandmarkets.com/research/kv93pj/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018" report to their offering. The analysts forecast the Global RNAi Drug Delivery market to grow at a CAGR of 21.80 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in RNA therapeutic development. The Global RNAi Drug Delivery market has also been witnessing some key technological advancements. However, the targeted delivery of RNA molecules is expected to pose a challenge to the growth of this market. Key vendors dominating this space are Alnylam Pharmaceuticals Inc., Isis Pharmaceuticals, Inc.,Merck & Co. Inc., and Tekmira Pharmaceuticals Corp. Other vendors mentioned in the report are Access Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Marina Biotech Inc., PhaseRx Inc., Quark Pharmaceuticals Inc., RXi Pharmaceuticals Corp., Silence Therapeutics plc, Sirnaomics Inc., Tacere Therapeutics Inc., and Traversa Therapeutics Inc. Commenting on the report, an analyst from the team said: Major advances in RNAi drug delivery are aimed at developing better delivery agents with excellent efficacy and the ability to target specific cells. For example, Bio-Path Holdings Inc. developed systemic delivery of antisense, small interfering RNA, and hydrophobic small molecules for treatment of various diseases using its neutral lipid drug delivery technology (neutral liposome). Similarly, Inovio's skin electroporation technology was used for the successful delivery of small interfering RNA molecules to skin in animal studies. Thus, technological innovations would further contribute to the growth of the Global RNAi Drug Delivery market. According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it. For more information visit http://www.researchandmarkets.com/research/kv..._rnai_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ObsEva SA Announces Appointments to Its Board of Directors and Scientific Advisory Board
GlobeNewswire - Fri Jan 17, 1:30AM CST
ObsEva, a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine, with a main focus on therapies for preterm labor, announced today new appointments to its Board of Directors and Scientific Advisory Board.
Global Acute Lung Injury Pipeline Review - H2 2013
M2 - Wed Dec 18, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/tzdsdv/acute_lung_injury) has announced the addition of the "Acute Lung Injury - Pipeline Review, H2 2013" report to their offering. 'Acute Lung Injury - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Lung Injury. Scope - A snapshot of the global therapeutic scenario for Acute Lung Injury. - A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Lung Injury pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Acute Lung Injury Therapeutics Development - GlaxoSmithKline plc - Quark Pharmaceuticals, Inc. - Discovery Laboratories, Inc. - Silence Therapeutics plc. - Altor BioScience Corporation - Mondobiotech Holding AG - Polyphor Ltd. - Implicit Bioscience Limited - KYORIN Pharmaceutical Co., Ltd. - Techpool Bio-Pharma Co., LTD. - Mayo Clinic - Faron Pharmaceuticals, Ltd. - APEPTICO Forschung und Entwicklung GmbH Drug Profiles - POL-6014 - dilmapimod - lucinactant - ALT-836 - KRP-109 - GSK-2586881 - etanercept - Atu-111 - interferon beta-1a - interferon beta-1a - aspirin - rosuvastatin calcium - Atu-134 - PanCyte - AP-301 - GSK-1995057 - CT-2009 - DasKloster-1000-04 - DasKloster-014101 - isoflurane - T-0901317 - Drug Targeting Leptin - TP-405 - Xib-1301 - Mesenchymal Stem Cells - Drug Inhibiting IGF-1R - TAT-SNAP-23 - rPAI-1 - S-1226 - S-1229 For more information visit http://www.researchandmarkets.com/research/tz...ung_injury
Liver Failure - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Liver Failure
M2 - Tue Aug 13, 11:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjjszl/liver_failure) has announced the addition of the "Liver Failure - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Liver Failure - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Liver Failure, complete with latest updates, and special features on late-stage and discontinued projects. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Liver Failure. - A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Liver Failure pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Silence Therapeutics plc. - EpiCept Corporation - Biotecnol SA - Ventria Bioscience - Conatus Pharmaceuticals Inc. - Ascenion GmbH - FCB-Pharmicell Co.,Ltd. For more information visit http://www.researchandmarkets.com/research/gj...er_failure About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Liver Fibrosis - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8fzcb9/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It provides information on the therapeutic development for liver fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for liver fibrosis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Liver Fibrosis. - A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Liver Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Liver Fibrosis Overview Therapeutics Development An Overview of Pipeline Products for Liver Fibrosis Companies Involved in Liver Fibrosis Therapeutics Development Liver Fibrosis - Therapeutics Assessment Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned - 7TM Pharma A/S - Angion Biomedica Corp - Bristol-Myers Squibb Company - Digna Biotech - FibroGen, Inc - GenKyoTex S.A - Genfit - Gilead Sciences, Inc - LG Life Sciences - La Jolla Pharmaceutical Company - Silence Therapeutics - Virobay Inc For more information visit http://www.researchandmarkets.com/research/8f...r_fibrosis
Lung Injury - Pipeline Review, H1 2013 Contains Latest News and Deals Relating To the Products
M2 - Wed Jun 05, 1:58PM CDT
Research and Markets (http://www.researchandmarkets.com/research/6pwvzt/lung_injury) has announced the addition of the "Lung Injury - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Lung Injury - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Injury. Lung Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Lung Injury. - A review of the Lung In
RNA Interference (RNAi) - Global Strategic Business Report
M2 - Wed Feb 13, 6:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/dqz252/rna_interference) has announced the addition of the "RNA Interference (RNAi) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for RNA Interference (RNAi) in US$ Million by the following Application Areas: Drug Discovery and Target Validation, Reagents, and siRNA Synthesis. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Outlook 2. Industry Overview 3. Market Outlook 4. Product Overview 5. Applications O
Amarantus elects Iain Ross to board
M2 - Mon Sep 01, 3:29AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) revealed on Friday the addition of Iain Ross to its board of directors.
Pulmonary Hypertension - Pipeline Review, H1 2014
M2 - Wed Jun 25, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/289bcz/pulmonary) has announced the addition of the "Pulmonary Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Activaero GmbH - Bayer AG - Ikaria Inc. - Proreo Pharma AG - Sanofi - Silence Therapeutics plc - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/289bcz/pulmonary
Global RNA Interference (RNAi) Therapy Market Outlook 2018
M2 - Tue Apr 01, 6:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hthtnb/global_rna) has announced the addition of the "Global RNA Interference (RNAi) Therapy Market Outlook 2018" report to their offering. The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry. Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts. There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be undruggable by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market. The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. With human proof of concept demonstrated, it is most likely that the RNAi companies would reformulate new delivery technology and enjoy the benefits. Global RNAi Therapy Report Findings: - Number of RNAi Based Drugs in Clinical Trials: 151 - Highest RNAi Clinical Trial in Preclinical Phase - Oncology Dominating the RNAi Based Drugs Clinical Trial Process - US Dominates RNAi Market & Clinical Trial Landscape Key Topics Covered: 1. Introduction to RNA Interference (RNAi) Therapy 2. Benefits of RNA Interference (RNAi) Therapy 3. RNA Interference (RNAi) Drug Delivery Mechanics 4. Global RNA Interference (RNAi) Therapy Market Overview 5. Global RNA Interference (RNAi) Market Dynamics 6. RNAi Clinical Pipeline by Phase, Indication & Country 7. Suspended & Discontinued RNAi Profiles 8. Competitive Landscape Companies Mentioned - Arrowhead Research - Alnylam Pharmaceuticals - Benitec Biopharma - Dicerna Pharmaceuticals - InteRNA Technologies - Isis Pharmaceuticals - RXi Pharmaceuticals - Santaris Pharma - Silence Therapeutics - Tekmira Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/hthtnb/global_rna
Global RNAi Drug Delivery Market 2014-2018: Read What's Trending
M2 - Wed Feb 19, 12:15PM CST
Research and Markets (http://www.researchandmarkets.com/research/kv93pj/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018" report to their offering. The analysts forecast the Global RNAi Drug Delivery market to grow at a CAGR of 21.80 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in RNA therapeutic development. The Global RNAi Drug Delivery market has also been witnessing some key technological advancements. However, the targeted delivery of RNA molecules is expected to pose a challenge to the growth of this market. Key vendors dominating this space are Alnylam Pharmaceuticals Inc., Isis Pharmaceuticals, Inc.,Merck & Co. Inc., and Tekmira Pharmaceuticals Corp. Other vendors mentioned in the report are Access Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Marina Biotech Inc., PhaseRx Inc., Quark Pharmaceuticals Inc., RXi Pharmaceuticals Corp., Silence Therapeutics plc, Sirnaomics Inc., Tacere Therapeutics Inc., and Traversa Therapeutics Inc. Commenting on the report, an analyst from the team said: Major advances in RNAi drug delivery are aimed at developing better delivery agents with excellent efficacy and the ability to target specific cells. For example, Bio-Path Holdings Inc. developed systemic delivery of antisense, small interfering RNA, and hydrophobic small molecules for treatment of various diseases using its neutral lipid drug delivery technology (neutral liposome). Similarly, Inovio's skin electroporation technology was used for the successful delivery of small interfering RNA molecules to skin in animal studies. Thus, technological innovations would further contribute to the growth of the Global RNAi Drug Delivery market. According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it. For more information visit http://www.researchandmarkets.com/research/kv..._rnai_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ObsEva SA Announces Appointments to Its Board of Directors and Scientific Advisory Board
GlobeNewswire - Fri Jan 17, 1:30AM CST
ObsEva, a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine, with a main focus on therapies for preterm labor, announced today new appointments to its Board of Directors and Scientific Advisory Board.
Global Acute Lung Injury Pipeline Review - H2 2013
M2 - Wed Dec 18, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/tzdsdv/acute_lung_injury) has announced the addition of the "Acute Lung Injury - Pipeline Review, H2 2013" report to their offering. 'Acute Lung Injury - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Lung Injury. Scope - A snapshot of the global therapeutic scenario for Acute Lung Injury. - A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Lung Injury pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Acute Lung Injury Therapeutics Development - GlaxoSmithKline plc - Quark Pharmaceuticals, Inc. - Discovery Laboratories, Inc. - Silence Therapeutics plc. - Altor BioScience Corporation - Mondobiotech Holding AG - Polyphor Ltd. - Implicit Bioscience Limited - KYORIN Pharmaceutical Co., Ltd. - Techpool Bio-Pharma Co., LTD. - Mayo Clinic - Faron Pharmaceuticals, Ltd. - APEPTICO Forschung und Entwicklung GmbH Drug Profiles - POL-6014 - dilmapimod - lucinactant - ALT-836 - KRP-109 - GSK-2586881 - etanercept - Atu-111 - interferon beta-1a - interferon beta-1a - aspirin - rosuvastatin calcium - Atu-134 - PanCyte - AP-301 - GSK-1995057 - CT-2009 - DasKloster-1000-04 - DasKloster-014101 - isoflurane - T-0901317 - Drug Targeting Leptin - TP-405 - Xib-1301 - Mesenchymal Stem Cells - Drug Inhibiting IGF-1R - TAT-SNAP-23 - rPAI-1 - S-1226 - S-1229 For more information visit http://www.researchandmarkets.com/research/tz...ung_injury
Liver Failure - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Liver Failure
M2 - Tue Aug 13, 11:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjjszl/liver_failure) has announced the addition of the "Liver Failure - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Liver Failure - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Liver Failure, complete with latest updates, and special features on late-stage and discontinued projects. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Liver Failure. - A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Liver Failure pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Silence Therapeutics plc. - EpiCept Corporation - Biotecnol SA - Ventria Bioscience - Conatus Pharmaceuticals Inc. - Ascenion GmbH - FCB-Pharmicell Co.,Ltd. For more information visit http://www.researchandmarkets.com/research/gj...er_failure About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Liver Fibrosis - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8fzcb9/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It provides information on the therapeutic development for liver fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for liver fibrosis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Liver Fibrosis. - A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Liver Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Liver Fibrosis Overview Therapeutics Development An Overview of Pipeline Products for Liver Fibrosis Companies Involved in Liver Fibrosis Therapeutics Development Liver Fibrosis - Therapeutics Assessment Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned - 7TM Pharma A/S - Angion Biomedica Corp - Bristol-Myers Squibb Company - Digna Biotech - FibroGen, Inc - GenKyoTex S.A - Genfit - Gilead Sciences, Inc - LG Life Sciences - La Jolla Pharmaceutical Company - Silence Therapeutics - Virobay Inc For more information visit http://www.researchandmarkets.com/research/8f...r_fibrosis
Lung Injury - Pipeline Review, H1 2013 Contains Latest News and Deals Relating To the Products
M2 - Wed Jun 05, 1:58PM CDT
Research and Markets (http://www.researchandmarkets.com/research/6pwvzt/lung_injury) has announced the addition of the "Lung Injury - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Lung Injury - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Injury. Lung Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Lung Injury. - A review of the Lung In
RNA Interference (RNAi) - Global Strategic Business Report
M2 - Wed Feb 13, 6:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/dqz252/rna_interference) has announced the addition of the "RNA Interference (RNAi) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for RNA Interference (RNAi) in US$ Million by the following Application Areas: Drug Discovery and Target Validation, Reagents, and siRNA Synthesis. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Outlook 2. Industry Overview 3. Market Outlook 4. Product Overview 5. Applications O
